PF 05206388

Drug Profile

PF 05206388

Alternative Names: Human embryonic stem cell derived retinal pigment epithelium - Pfizer; PF-05206388; PF-5206388

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer; University College London
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Age-related macular degeneration

Most Recent Events

  • 29 Mar 2017 Pfizer initiateslong term safey follow-up study for Age-related macular degeneration in United Kingdom (NCT03102138)
  • 04 Jan 2017 Pfizer suspends participant enrolment in the phase I trial in Age-related macular degeneration in United Kingdom (NCT01691261)
  • 01 Jun 2015 Phase-I clinical trials in Age-related macular degeneration (In the elderly) in United Kingdom (Intraocular; Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top